| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
1,3-Propanesultam does not have a defined pharmacological receptor target, as it is primarily a chemical building block rather than a therapeutic agent. Its utility lies in its chemical reactivity as a sultam, which can be used to introduce sulfonamide functionalities into target molecules. The compound may be used as a precursor for the synthesis of various bioactive compounds, but it does not have intrinsic pharmacological activity itself.
|
|---|---|
| ln Vitro |
In vitro, 1,3-Propanesultam serves as a chemical intermediate for the synthesis of active compounds. As a sultam, it can participate in various organic reactions, including nucleophilic substitution and ring-opening reactions, to generate diverse sulfonamide-containing molecules. No specific pharmacological activities, such as receptor binding or enzyme inhibition, have been reported for this compound itself. Its primary in vitro utility is as a synthetic building block.
|
| ln Vivo |
No in vivo pharmacological activity has been reported for 1,3-Propanesultam, as it is not intended for therapeutic use. Its applications are confined to chemical synthesis, where it serves as a building block for the preparation of biologically active compounds. The compound is not administered to animals for pharmacological evaluation. Its role in research is strictly as a chemical intermediate.
|
| Enzyme Assay |
Non-cellular assays are not applicable for this compound, as it is a chemical intermediate and is not evaluated in pharmacological binding assays. Its characterization typically involves analytical methods such as NMR, HPLC, and mass spectrometry to confirm structure and purity. The compound's identity and purity are verified using standard organic chemistry analytical techniques. No receptor binding or enzyme inhibition assays are performed with this sultam.
|
| Cell Assay |
Cell-based assays are not performed with 1,3-Propanesultam as a test article. It is used in the chemical synthesis of compounds that are subsequently evaluated for biological activity in cell-based assays. The intermediate itself is not tested in cell-based assays, as it is a synthetic precursor rather than a pharmacologically active compound. Its primary use is in medicinal chemistry for the synthesis of drug candidates.
|
| Animal Protocol |
In vivo animal studies are not conducted with 1,3-Propanesultam as a primary test agent. It is used in the chemical synthesis of active compounds that are then evaluated in animal models for pharmacological efficacy. The intermediate itself is not administered to animals. Its role in research is strictly as a chemical building block for the synthesis of drug candidates.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not applicable for this compound, as it is a chemical intermediate rather than a drug candidate. The compound has a molecular weight of 121.16 g/mol and is a small polar molecule. No pharmacokinetic parameters have been characterized for this intermediate, as it is a research chemical rather than a therapeutic agent.
|
| Toxicity/Toxicokinetics |
No toxicity data have been reported for 1,3-Propanesultam in the available literature. As a chemical reagent, it should be handled with standard laboratory safety precautions. The compound is for research use only and is not for human use. Its safety profile has not been extensively characterized. Proper personal protective equipment should be used during handling.
|
| References |
[1]. Rolfe A, et al. Triazole-containing isothiazolidine 1,1-dioxide library synthesis: one-pot, multi-component protocols for small molecular probe discovery. ACS Comb Sci. 2011 Sep 12;13(5):511-7.
|
| Additional Infomation |
1,3-Propanesultam is a research chemical, not an approved pharmaceutical drug. It is a bioactive chemical used for the synthesis of active compounds. Also known as 1,1-Dioxoisothiazolidine, it is a versatile building block in organic synthesis. The compound is available as a high-purity research reagent and is used in medicinal chemistry for the preparation of sulfonamide-containing pharmaceuticals and biologically active molecules. It is not intended for human therapeutic use.
|
| Molecular Formula |
C3H7NO2S
|
|---|---|
| Molecular Weight |
121.16
|
| Exact Mass |
121.02
|
| CAS # |
5908-62-3
|
| PubChem CID |
642157
|
| Appearance |
Colorless to light yellow liquid（Density：1.326±0.06 g/cm3）
|
| LogP |
0.719
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
7
|
| Complexity |
143
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S1(C([H])([H])C([H])([H])C([H])([H])N1[H])(=O)=O
|
| InChi Key |
XGYCWCIGCYGQFU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H7NO2S/c5-7(6)3-1-2-4-7/h4H,1-3H2
|
| Chemical Name |
1,2-thiazolidine 1,1-dioxide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.2535 mL | 41.2677 mL | 82.5355 mL | |
| 5 mM | 1.6507 mL | 8.2535 mL | 16.5071 mL | |
| 10 mM | 0.8254 mL | 4.1268 mL | 8.2535 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
